We are proud to announce that the European Regional Development Fund (EFRE) funds the realization of the imuStain project at imusyn.
As of March 2018, our recombinant blood group antigens (rBGA) and DaraEx can be purchased from inno-train Diagnostik GmbH.
We have developed a new, patent-pending remedy for anti-CD38 antibody interference in immunohematological pre-transfusion testing, called "DaraEx".
EN ISO 13485:2016, issued June 17th, 2020
Marta Albis Camps joined imusyn in 2001. She graduated from the University of the Balearic Islands, Spain, and received her MSc in Biology in 1993. Before joining imusyn, she served as a postgraduate researcher at the Humboldt University Berlin, Charité, in the Department of Haematology and Oncology. Marta Albis Camps has extensive experience in molecular genetics as well as regulatory affairs and safety. As head of imusyn’s Executive Leadership Team she has comprehensive responsibilities for all aspects of the company's medical, regulatory and safety activities.
Clemens Schneeweiß joined imusyn in 2009. He graduated from the Philipps University Marburg and received his Diploma in Human Biology in 2003. He obtained his PhD in Biochemistry in 2008 from the Jacobs University Bremen, where his research focused on tapasin dependency, peptide loading, and intracellular trafficking of major histocompatibility complex (MHC) class I molecules. Dr. Schneeweiß has extensive experience in cell biology, protein chemistry and protein engineering. As head of imusyn’s R&D Department he has comprehensive responsibilities for all aspects of the company's research activities and strategic orientation.